Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy
about
sameAs
API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysisSurgery for Non-Hodgkin's LymphomaClinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)Rare Neoplasia of the StomachMolecular Pathogenesis of MALT LymphomaFAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphomaIdentification of a genetic marker of Helicobacter pylori strains involved in gastric extranodal marginal zone B cell lymphoma of the MALT-type.Role of ancillary techniques in diagnosing and subclassifying non-Hodgkin's lymphomas on fine needle aspiration cytology.Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphomaRegression of idiopathic thrombocytopenic purpura after endoscopic mucosal resection of gastric mucosa associated lymphoid tissue lymphomaClassification of lymphoid neoplasms: the microscope as a tool for disease discovery.Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: possible correlation with stage and treatment response.Deregulation of a distinct set of microRNAs is associated with transformation of gastritis into MALT lymphoma.Trisomy 3 may predict a poor response of gastric MALT lymphoma to Helicobacter pylori eradication therapy.B-cell receptor signaling as a driver of lymphoma development and evolution.Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma.Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomasHelicobacter and gastric MALT lymphoma.T(11;18)(q21;q21)-positive gastrointestinal MALT lymphomas are heterogeneous with respect to the V(H) gene mutation status.A case of primary low grade mucosa associated lymphoid tissue (MALT) lymphoma of the oesophagusActivation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis.Molecular biology of gastric MALT lymphoma: application in clinical management.Chromosomal translocation t(11;18)(q21;q21) in gastrointestinal mucosa associated lymphoid tissue lymphomaReview article: the treatment of refractory Helicobacter pylori infection.Evaluation of the association of nine Helicobacter pylori virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma.Distinct methylated profiles in Helicobacter pylori dependent and independent gastric MALT lymphomas.Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series.Molecular pathology in the diagnosis and treatment of non-Hodgkin's lymphomas.Mucosa-associated lymphoid tissue lymphomas with t(11;18)(q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways.API2-MALT1 fusion defines a distinctive clinicopathologic subtype in pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomasTargeting endogenous inhibitors of apoptosis for treatment of cancer, stroke and multiple sclerosis.Primary thymic extranodal marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue type exhibits distinctive clinicopathological and molecular features.Molecular pathogenesis of mucosal-associated lymphoid tissue (MALT) lymphoma.Issues in oral nanoparticle drug carrier uptake and targeting.Genetic and epigenetic factors involved in B-cell lymphomagenesis.Low Grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Clinicopathological Factors Associated with Helicobacter pylori Eradication and Tumor RegressionClinicopathologic Study of Chromosomal Aberrations in Ocular Adnexal Lymphomas of Korean PatientsLymphoid proliferations of indeterminate malignant potential arising in adults with common variable immunodeficiency disorders: unusual case studies and immunohistological review in the light of possible causative events
P2860
Q26765188-18EDF248-39CB-4525-B6F4-A5DE75ED7466Q26771421-A4BC34E0-799C-47FE-AA9E-B9EB5495D672Q26771654-759E8711-5DCB-42FB-84FC-1B88E6800772Q26775428-EE05C81A-3B88-4DAC-BC36-38D594C484C1Q26825394-86A60E99-CC33-4878-85E1-7F0C890B73D8Q28767089-224DE366-D2FB-4673-A0DC-25B5DE56BDFEQ31078515-7128FACD-6824-4E7C-8E3C-0DB77DA82CECQ33256872-BD1CD853-A3CC-424D-8EE1-A2D473CBC5FEQ33260939-20FB9B24-BD20-49B8-B56A-91263A1DB17DQ33363198-49A287D6-7FFA-45E1-8204-EF8D799456B3Q33386690-5140FA0C-AE31-47BD-80A7-EB7A3EE0EAB0Q33403350-F8904A89-1226-44B5-96A8-705055E8C44FQ34134744-D34D9FC8-F5CB-4FC8-87B3-2C0AAF6B9E42Q34259217-C25E422B-D8AA-4B16-B582-21349F9C9AB5Q34382550-7DDFE6D4-3880-4463-B4C8-7634AE99FBA8Q34398579-9BC0E2EB-EFA3-4482-BD49-04A1F41D84ABQ34457270-6875A2E4-B96C-429E-8095-71AB56BB9268Q34562708-D45E672C-FE6D-4724-A4C1-86A254D6A71AQ34600976-A3CF3B7E-088A-411C-B59F-14C25F3A9D1BQ34612166-DFCE4A9B-1514-461A-9E37-000F91B0CA2EQ34739152-9F52B2D9-40FC-4457-9EFF-3EB24D35587BQ34835324-EEC421FE-B47A-40A6-AD61-B311ED20BB4EQ35022121-3EEDF506-A63F-4AF9-A5E2-88EB6419A299Q35033500-F0F53B38-22B1-4566-8C1D-61634E2E83DDQ35145092-BF0178BA-CF60-4E66-B470-3660DF2ECA93Q35549290-68C7ED65-4ADD-4106-AADF-1D1CFE953134Q35595610-F9751F5D-74DA-4FA2-BDB8-1E37A068A3C5Q35596211-6AC820ED-C980-45BA-B1C0-3C11670BCD76Q35644667-018EB4A4-6C6F-415E-8B52-48B61E24A683Q35747503-7FA8BB37-CC11-4AD5-905C-7E8AE75952B3Q35749277-A9F25748-2DEF-4275-883D-CFCBF163051FQ35761034-88AE1C56-54A1-4C07-A2DA-D8A94F387A32Q35782897-FDBCCC29-4579-4610-87FF-957373D9681DQ35788892-E75AA644-D949-449F-9D7E-49B526A65E37Q35808370-B2B6047D-B93B-44E8-8E62-7DBE921FDFFCQ35809222-5AE83363-DBC1-40BA-8066-EE66DBFA34AFQ35911855-A1AD236D-D1F2-4D53-970D-871E4CCF5B2FQ35997174-1985ACC4-2B3E-493F-9237-07BE82BCA101Q36127256-55D8B5EF-3991-45E7-A8F6-F136F46FEB5FQ36190436-69DC28FB-D4EB-4589-80D0-F9B410DF75BE
P2860
Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Resistance of t(11;18) positiv ...... ter pylori eradication therapy
@ast
Resistance of t(11;18) positiv ...... ter pylori eradication therapy
@en
Resistance of t(11;18) positiv ...... ter pylori eradication therapy
@nl
type
label
Resistance of t(11;18) positiv ...... ter pylori eradication therapy
@ast
Resistance of t(11;18) positiv ...... ter pylori eradication therapy
@en
Resistance of t(11;18) positiv ...... ter pylori eradication therapy
@nl
prefLabel
Resistance of t(11;18) positiv ...... ter pylori eradication therapy
@ast
Resistance of t(11;18) positiv ...... ter pylori eradication therapy
@en
Resistance of t(11;18) positiv ...... ter pylori eradication therapy
@nl
P2093
P1433
P1476
Resistance of t(11;18) positiv ...... ter pylori eradication therapy
@en
P2093
A Lavergne-Slove
A Ruskon-Fourmestraux
J C Rambaud
P G Isaacson
R A Hamoudi
P356
10.1016/S0140-6736(00)03571-6
P407
P577
2001-01-06T00:00:00Z